Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)

Patient eligibility criteria in accordance to the summary of Product Characteristics: * Patients with confirmed diagnosis of acute myeloid leukemia according to the World Health Organization (WHO) classification (including de novo AML, t-AML and s-AML) in first complete remission (defined as less than 5% blasts in a normocellular bone marrow assessed prior to the treatment start) * AMLSG BiO participation incl. favourable opinion * Presence of NPM1 mutation, CBFB-MYH11 or MLL-AF9 fusion genes as assessed in one of the central AMLSG reference laboratories. * Measurable MRD values (non-negative values after consolidation therapy or increase in values over the threshold during follow-up in complete remission) * The patient must be informed of the observation and written informed consent regarding data privacy obtained. * Consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and all other treating physicians about observation participation * No continuing systemic treatment with clonidine, steroids, and/or H2 receptor blocking agents.